Treatment of childhood cancer in China: Current status and future direction
Authors:
Open Access
- 27 September 2020
- journal article
- editorial
- Published by Wiley in Pediatric Investigation
- Vol. 4 (3) , 153-156
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic LeukemiaJAMA Oncology, 2020
- Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG‐ALL 2008: The first nation‐wide prospective multicenter study in ChinaAmerican Journal of Hematology, 2018
- Philadelphia chromosome-positive acute lymphoblastic leukemia in China: a retrospective study from the Chinese Childhood Cancer GroupLeukemia & Lymphoma, 2016
- Consolidating the social health insurance schemes in China: towards an equitable and efficient health systemThe Lancet, 2015
- Incidence, mortality and survival of childhood cancer in China during 2000–2010 period: A population-based studyCancer Letters, 2015
- Pediatric Medical Care System in China Has Significantly Reduced Abandonment of Acute Lymphoblastic Leukemia TreatmentJournal of Pediatric Hematology/Oncology, 2015
- Paediatric cancer in low-income and middle-income countriesThe Lancet Oncology, 2013
- A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantationBlood, 2012
- A report about treatment refusal and abandonment in children with acute lymphoblastic leukemia in China, 1997–2007Leukemia Research, 2011
- Professor Ya-mei HuMedical and Pediatric Oncology, 1999